TG Therapeutics (NASDAQ:TGTX) Shares Up 4.8%

TG Therapeutics, Inc. (NASDAQ:TGTX)’s share price shot up 4.8% during mid-day trading on Thursday . The stock traded as high as $14.63 and last traded at $14.48. 1,638,056 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 4,168,954 shares. The stock had previously closed at $13.82.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $39.00 target price on shares of TG Therapeutics in a research note on Thursday. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 24th. The Goldman Sachs Group lifted their target price on TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $25.00 price target on shares of TG Therapeutics in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of TG Therapeutics in a research report on Thursday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

TG Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The company has a 50-day moving average of $15.11 and a 200 day moving average of $13.91. The firm has a market cap of $2.13 billion, a P/E ratio of 689.34 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.03. The company had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. During the same quarter in the previous year, the company earned ($0.39) EPS. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post -0.12 EPS for the current year.

Insiders Place Their Bets

In other news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TGTX. Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics during the third quarter worth approximately $1,219,000. Hussman Strategic Advisors Inc. bought a new position in TG Therapeutics in the 3rd quarter worth approximately $439,000. Rhenman & Partners Asset Management AB lifted its holdings in TG Therapeutics by 190.9% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 160,000 shares of the biopharmaceutical company’s stock worth $1,338,000 after buying an additional 105,000 shares in the last quarter. Rafferty Asset Management LLC boosted its position in TG Therapeutics by 183.2% in the 3rd quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock valued at $7,163,000 after buying an additional 554,309 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter valued at $511,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.